BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioForce Nanosciences Holdings, Inc. (BFNH.OB) Reports First Nano eNabler System Sale to a Commercial User


2/9/2009 12:15:22 PM

AMES, IA--(Marketwire - February 09, 2009) - BioForce Nanosciences Holdings, Inc. (OTCBB: BFNH), a producer of products and solutions for academic researchers and commercial users based upon its ultra-micro to nano scale fluid deposition platform, today announced the first ever sale of a Nano eNabler™ System to a commercial user. The sale to an international semiconductor manufacturer was completed by BioForce's Continental European distributor, NanoandMore GmbH.

In addition to the significant milestone of being the first Nano eNabler System sale to a commercial user, this transaction marks the first sale to a user who intends to deploy the Nano eNabler in a production rather than research laboratory environment. This reinforces BioForce's vision that a need exists for the Nano eNabler in production environments where commercial users seek to manufacture products, such as biosensors and other diagnostic devices, requiring ultra-micro to nano scale fluid deposition.

NanoandMore GmbH's Chief Executive Officer, Peer Burshille, said, "We are continuing to see significant interest among European sales prospects in the Nano eNabler's unique capabilities. This interest comes from both academic institutions and industrial companies. This marks our company's fifth Nano eNabler System sale, and we expect that our sales of BioForce's products in 2009 will exceed those of previous years."

"The fact that this semiconductor manufacturer has made this capital investment during an economic climate when many companies are deferring capital expenditures demonstrates that the Nano eNabler is essential in order for strategically important advances to be made in both biological and non-biological areas."

BioForce's Chief Executive Officer, Kerry Frey, said, "I see this transaction as significant as it involves a commercial user whose production requirements could result in a need for multiple Nano eNabler systems. Establishing that there is a market for the Nano eNabler as a production tool has been one of our key objectives, and is a cornerstone of our long-term business plan. It is indeed gratifying to have achieved this important milestone."

For further information about this release please contact Greg Brown, Chief Financial Officer of BioForce at (515) 233-8333 ext. 118, or Rich Kaiser, Investor Relations at (800) 631-8127.

About BioForce Nanosciences Holdings, Inc.

BioForce Nanosciences produces products and solutions for academic researchers and industrial companies based upon its ultra-micro to nano scale fluid deposition platform. BioForce's flagship product, the Nano eNabler™ molecular printer, gives the Company and its customers a platform for development and discovery by depositing fluid onto surfaces with nanometer spatial precision. BioForce technology is being used in biological areas such as biosensor functionalization; patterning and cell adhesion; and the printing of proteins to guide neural cell growth, as well as in non-biological applications. For more information, visit http://www.bioforcenano.com or call 515-233-8333.

This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in BioForce Nanosciences' most recent filings with the Securities and Exchange Commission. BioForce Nanosciences' actual results could differ materially from such forward-looking statements. BioForce assumes no duty to update these statements at any future date.


Company Contact:
Gregory D. Brown
Chief Financial Officer
515-233-8333 ext# 118
Email Contact

Investor Relations:
Yes International
Rich Kaiser
800-631-8127



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES